National Cancer Institute (NCI): Osteosarcoma trials

The registry lists 52 Osteosarcoma studies with National Cancer Institute (NCI) as lead sponsor. 1 are open to participants now and 26 have results posted.

Phase 1 18Phase 2 33Phase 3 2No phase 2(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Trastuzumab Deruxtecan (DS-8201a) for the Treatment of Recurrent or Refractory Osteosarcoma, Wilms Tumor, and Desmoplastic Small Round Cell TumorRecruitingNCT04616560Phase 2
• Testing the Combination of Two Immunotherapy Drugs (Magrolimab and Dinutuximab) in Patients With Relapsed or Refractory Neuroblastoma or Relapsed OsteosarcomaTerminatedNCT04751383Phase 1Results posted
• Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment TrialActive, not recruitingNCT04320888Phase 2Results posted
• Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment TrialActive, not recruitingNCT04284774Phase 2Results posted
• Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutations (A Pediatric MATCH Treatment Trial)Active, not recruitingNCT04195555Phase 2Results posted
• Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)Active, not recruitingNCT03698994Phase 2Results posted
• Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial)CompletedNCT03526250Phase 2Results posted
• Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)CompletedNCT03233204Phase 2Results posted
• Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)CompletedNCT03220035Phase 2Results posted
• Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial)Active, not recruitingNCT03213704Phase 2Results posted
• Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)CompletedNCT03213678Phase 2Results posted
• Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)CompletedNCT03213665Phase 2Results posted
• Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)Active, not recruitingNCT03213652Phase 2Results posted
• Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)Active, not recruitingNCT03155620Phase 2Results posted
• Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare TumorsActive, not recruitingNCT02867592Phase 2Results posted
• Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Sarcoma That Cannot Be Removed by SurgeryCompletedNCT02500797Phase 2Results posted
• Glembatumumab Vedotin in Treating Patients With Recurrent or Refractory OsteosarcomaCompletedNCT02487979Phase 2Results posted
• Dinutuximab in Combination With Sargramostim in Treating Patients With Recurrent OsteosarcomaCompletedNCT02484443Phase 2Results posted
• Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or SarcomasCompletedNCT02304458Phase 1/2Results posted
• Cabozantinib S-malate in Treating Patients With Relapsed Osteosarcoma or Ewing SarcomaActive, not recruitingNCT02243605Phase 2Results posted
• Eribulin Mesylate in Treating Patients With Recurrent or Refractory OsteosarcomaCompletedNCT02097238Phase 2Results posted
• Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory SarcomaCompletedNCT01614795Phase 2Results posted
• Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic SarcomaCompletedNCT01154452Phase 1/2Results posted
• Temsirolimus and Cixutumumab in Treating Patients With Locally Advanced, Metastatic, or Recurrent Soft Tissue Sarcoma or Bone SarcomaCompletedNCT01016015Phase 2Results posted
• Cixutumumab in Treating Patients With Relapsed or Refractory Solid TumorsCompletedNCT00831844Phase 2Results posted
• Sorafenib in Treating Patients With Soft Tissue Sarcomas (Extremity Sarcoma Closed to Entry as of 5/30/07)CompletedNCT00330421Phase 2Results posted
• Depsipeptide (Romidepsin) in Treating Patients With Metastatic or Unresectable Soft Tissue SarcomaCompletedNCT00112463Phase 2Results posted
• A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed OsteosarcomaSuspendedNCT05691478Phase 2/3
• Testing a New Immune Cell Therapy, GD2-Targeted Modified T-cells (GD2CART), in Children, Adolescents, and Young Adults With Relapsed/Refractory Osteosarcoma and Neuroblastoma, GD2-CAR PERSIST TrialSuspendedNCT04539366Phase 1
• A Phase I Trial of T Cells Expressing an Anti-GD2 Chimeric Antigen Receptor in Children and Young Adults With GD2+ Solid TumorsCompletedNCT02107963Phase 1
• RO4929097 in Children With Relapsed/Refractory Solid or CNS Tumors, Lymphoma, or T-Cell LeukemiaWithdrawnNCT01236586Phase 1
• A Phase I Study of Pazopanib as a Single Agent for Children With Refractory Solid TumorsWithdrawnNCT01130623Phase 1
• Informed Consent in Pediatric Cancer TrialsCompletedNCT00923650
• Cixutumumab and Doxorubicin Hydrochloride in Treating Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue SarcomaCompletedNCT00720174Phase 1
• HGS-ETR2 to Treat Children With Solid TumorsTerminatedNCT00428272Phase 1
• Ixabepilone in Treating Young Patients With Refractory Solid TumorsCompletedNCT00331643Phase 2
• Oxaliplatin and Irinotecan in Treating Young Patients With Refractory Solid Tumors or LymphomasCompletedNCT00101270Phase 1
• Tanespimycin in Treating Young Patients With Recurrent or Refractory Leukemia or Solid TumorsCompletedNCT00093821Phase 1
• Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous TreatmentCompletedNCT00091182Phase 2
• Erlotinib and Temozolomide in Treating Young Patients With Recurrent or Refractory Solid TumorsCompletedNCT00077454Phase 1
• Imatinib Mesylate in Treating Patients With Advanced Soft Tissue Sarcoma or Bone SarcomaCompletedNCT00031915Phase 2
• Imatinib Mesylate in Treating Patients With Relapsed or Refractory Solid Tumors of ChildhoodCompletedNCT00030667Phase 2
• Eligibility Screening for a NCI Pediatric Oncology Branch Research StudyCompletedNCT00026780
• Chemotherapy With or Without Trastuzumab in Treating Patients With Metastatic OsteosarcomaCompletedNCT00023998Phase 2
• Vaccine Therapy in Treating Patients With Metastatic CancerCompletedNCT00020267Phase 1
• Combination Chemotherapy Before and After Surgery in Treating Patients With OsteosarcomaTerminatedNCT00019864Phase 2
• Liposomal Doxorubicin in Treating Children With Refractory Solid TumorsCompletedNCT00019630Phase 1
• Flavopiridol in Treating Children With Relapsed or Refractory Solid Tumors or LymphomasCompletedNCT00012181Phase 1
• 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Advanced Epithelial Cancer, Malignant Lymphoma, or SarcomaCompletedNCT00004241Phase 1
• A Phase I Study of OncoLAR® (Registered Trademark) (NSC 685403) With/Without Tamoxifen in Patients With OsteosarcomaCompletedNCT00001436Phase 1
• Osteosarcoma Study #2: A Randomized Trial of Pre-Surgical Chemotherapy vs. Immediate Surgery and Adjuvant Chemotherapy in the Treatment of Non-Metastatic Osteosarcoma. A Pediatric Oncology Group Phase III StudyCompletedNCT00001217Phase 3
• A Pilot Study for the Treatment of Patients With Metastatic and High Risk Sarcomas and Primitive Neuroectodermal TumorsCompletedNCT00001209Phase 1